Highlight
– Rademikibart, a next-generation IL-4Rα inhibitor, provides sustained lung function improvements in moderate-to-severe asthma patients without significantly increasing eosinophil counts.
– Unlike prior anti-IL-4Rα agents, exploratory analyses suggest rademikibart does not induce hypereosinophilia as a class effect.
– The randomized phase 2b trial showed stable or reduced eosinophil counts over 24 weeks compared to placebo.
– Larger and confirmatory studies are necessary to validate these findings and discern clinical implications.
